Devices, Diagnostics, and Drugs to Address Women’s Needs Product Development Partnership Fact Sheets
The new, four-year Devices, Diagnostics, and Drugs to Address Women’s Needs Product Development Partnership (D3AWN PDP) is tapping into PATH’s deep PDP expertise to develop and introduce a portfolio of devices, diagnostics, and drugs to prevent or manage preeclampsia/eclampsia (PE/E) and PPH. The D3AWN PDP is advancing affordable, accessible, safe, and effective tools for sub-Saharan communities. Solutions include:
- Heat-stable FDT for PPH prevention: Sublingual oxytocin in heat-stable, fast dissolving tablet.
- Reusable, electricity-free infusion pump for the delivery of lifesaving nutrients, fluids, and medicines: RELI Delivery System.
- Uterine balloon tamponade for the management of PPH: Sinapi Ellavi Uterine Balloon Tamponade.
- Urinary dipstick test with protein to creatinine ratiometric measurement for improved preeclampsia screening
Publication date: June 2019
Urinary dipstick test with protein to creatinine ratiometric measurement for improved preeclampsia screening
230.2 KB PDF
Advancing urinary dipstick tests that are accurate and appropriate for use during routine antenatal care services in low-resource areas.
RELI Delivery System
177 KB PDF
The RELI Delivery System combines the low cost and simplicity of non-electric disposable pumps with the functionality and accuracy of electronic devices, without the need for proprietary consumables.
Sinapi Ellavi Uterine Balloon Tamponade
232.4 KB PDF
The Ellavi UBT is a preassembled, ready to use low-cost medical device (CE Mark) with a unique mechanism of action and several advantages over UBT products on the market and existing stop-gap measures.
Sublingual Oxytocin in Heat-stable, Fast-Dissolving Tablet
297.4 KB PDF
Sublingual oxytocin in heat-stable fast-dissolving tablets offers a flexible needle-free presentation that can be available in multiple packaging options, making it easy to administer for the prevention of PPH.
- Urinary dipstick test with protein to creatinine ratiometric measurement for improved preeclampsia screening 230.2 KB PDF